Reporting owner · CIK 0001666236

Krognes Steve E.

SEC Form 4 history across 1 companies, 6 transactions and 2 filings.

DIRGuardant Health, Inc.
Open-market transaction mix0% buys0 buys · 4 sales

Available history · May 31, 2026 – Sep 16, 2026

Filings2Form 4 records
Buying$00 purchases
Selling$1.2M4 sales
Net value−$1.2MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Krognes Steve E. transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
GHGuardant Health, Inc.
Krognes Steve E.DIRS · saleSEC filing ↗-$172kView disclosure →
GHGuardant Health, Inc.
Krognes Steve E.DIRS · saleSEC filing ↗-$229kView disclosure →
GHGuardant Health, Inc.
Krognes Steve E.DIRS · saleSEC filing ↗-$578kView disclosure →
GHGuardant Health, Inc.
Krognes Steve E.DIRS · saleSEC filing ↗-$192kView disclosure →
GHGuardant Health, Inc.
Krognes Steve E.DIRM · exerciseDerivative securitySEC filing ↗$0View disclosure →
GHGuardant Health, Inc.
Krognes Steve E.DIRM · exerciseSEC filing ↗$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

sale at Guardant Health, Inc. on Sep 16, 2026 valued at $172,330.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Guardant Health, Inc. on Sep 16, 2026 valued at $172,330.

Review SEC filing

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202600$0.00$0.00$0.00
Sep 202604$0.00$1,172,885.70-$1,172,885.70

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$293.2K
Median P/S size$210.8K
Direct6
Indirect0
Sep 16, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in available history

A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

5 observations · May 31, 2026 – Sep 16, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 16, 20267,906 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
May 31, 202619,516Jun 1, 2026View transaction
Sep 16, 202613,477Sep 17, 2026View transaction
Sep 16, 202610,177Sep 17, 2026View transaction
Sep 16, 20268,877Sep 17, 2026View transaction
Sep 16, 20267,906Sep 17, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Krognes Steve E. Insider Activity FAQ

SEC Form 4 context

Who is Krognes Steve E.?

Krognes Steve E. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001666236.

Which companies has Krognes Steve E. reported transactions for?

Guardant Health, Inc., Denali Therapeutics Inc.

When was Krognes Steve E.'s latest insider buy?

No open-market insider purchase is available for this period.

When was Krognes Steve E.'s latest insider sale?

sale at Guardant Health, Inc. on Sep 16, 2026 valued at $172,330.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.